Back to available technologies
Targeting the Wnt-beta-catenin Signaling Pathway to Augment the Efficacy of Checkpoint Inhibitor Immunotherapy
This technology is associated with theuse of Wnt-Beta cateniin antagonists to circumvent resistance and enhance the efficacy of currently available immune checkpoint inhibitors in patients with advanced cancer.
Interested in this Technology?
Submit your interest below.